Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
1.250
-0.070 (-5.30%)
Nov 6, 2025, 4:00 PM EST - Market closed
Nexalin Technology Revenue
Nexalin Technology had revenue of $70.59K in the quarter ending June 30, 2025, with 163.00% growth. This brings the company's revenue in the last twelve months to $174.81K, up 16.42% year-over-year. In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth.
Revenue (ttm)
$174.81K
Revenue Growth
+16.42%
P/S Ratio
91.14
Revenue / Employee
$29,136
Employees
6
Market Cap
21.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
NXL News
- 1 day ago - Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia - GlobeNewsWire
- 7 days ago - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel - GlobeNewsWire
- 16 days ago - Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies - GlobeNewsWire
- 24 days ago - Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs - GlobeNewsWire
- 27 days ago - Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit - GlobeNewsWire
- 4 weeks ago - Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday? - Benzinga
- 4 weeks ago - Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology - GlobeNewsWire